I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| cardiac muscle cell | 7 studies | 60% ± 14% | |
| pericyte | 4 studies | 26% ± 12% | |
| fibroblast | 3 studies | 32% ± 11% | |
| macrophage | 3 studies | 18% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| cardiac muscle cell | 7 studies | 60% ± 14% | |
| pericyte | 4 studies | 26% ± 12% | |
| fibroblast | 3 studies | 32% ± 11% | |
| macrophage | 3 studies | 18% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| heart | 6 studies | 31% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| muscle | 100% | 394234.86 | 803 / 803 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 12.89 | 1 / 1 |
| heart | 99% | 270823.04 | 849 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 76% | 5.39 | 22 / 29 |
| prostate | 26% | 1971.60 | 63 / 245 | 15% | 69.92 | 75 / 502 |
| blood vessel | 37% | 1551.74 | 492 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 31% | 29.48 | 14 / 45 |
| peripheral blood | 30% | 485.72 | 281 / 929 | 0% | 0 | 0 / 0 |
| lung | 28% | 107.50 | 159 / 578 | 1% | 1.11 | 17 / 1155 |
| thymus | 25% | 187.66 | 165 / 653 | 1% | 1.63 | 6 / 605 |
| adipose | 26% | 145.64 | 308 / 1204 | 0% | 0 | 0 / 0 |
| skin | 22% | 259.40 | 403 / 1809 | 3% | 0.13 | 15 / 472 |
| breast | 22% | 316.15 | 103 / 459 | 2% | 1.73 | 24 / 1118 |
| esophagus | 19% | 197.88 | 271 / 1445 | 2% | 0.03 | 3 / 183 |
| intestine | 18% | 66.23 | 173 / 966 | 2% | 0.04 | 8 / 527 |
| uterus | 11% | 41.96 | 19 / 170 | 7% | 4.55 | 32 / 459 |
| brain | 16% | 63.84 | 429 / 2642 | 1% | 0.02 | 4 / 705 |
| pancreas | 10% | 62.14 | 33 / 328 | 6% | 0.27 | 11 / 178 |
| ovary | 14% | 36.68 | 25 / 180 | 2% | 0.06 | 10 / 430 |
| stomach | 13% | 43.97 | 45 / 359 | 2% | 0.03 | 5 / 286 |
| liver | 12% | 49.20 | 28 / 226 | 1% | 0.04 | 3 / 406 |
| adrenal gland | 11% | 87.86 | 29 / 258 | 1% | 0.24 | 2 / 230 |
| kidney | 11% | 35.06 | 10 / 89 | 0% | 0.01 | 4 / 901 |
| spleen | 10% | 26.73 | 24 / 241 | 0% | 0 | 0 / 0 |
| bladder | 5% | 8.24 | 1 / 21 | 2% | 0.28 | 11 / 504 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006942 | Biological process | regulation of striated muscle contraction |
| GO_0007507 | Biological process | heart development |
| GO_0002026 | Biological process | regulation of the force of heart contraction |
| GO_0042694 | Biological process | muscle cell fate specification |
| GO_0060048 | Biological process | cardiac muscle contraction |
| GO_0055010 | Biological process | ventricular cardiac muscle tissue morphogenesis |
| GO_0055003 | Biological process | cardiac myofibril assembly |
| GO_0060047 | Biological process | heart contraction |
| GO_0098735 | Biological process | positive regulation of the force of heart contraction |
| GO_0030308 | Biological process | negative regulation of cell growth |
| GO_0005856 | Cellular component | cytoskeleton |
| GO_0097512 | Cellular component | cardiac myofibril |
| GO_0030016 | Cellular component | myofibril |
| GO_0015629 | Cellular component | actin cytoskeleton |
| GO_0030017 | Cellular component | sarcomere |
| GO_0005829 | Cellular component | cytosol |
| GO_0031672 | Cellular component | A band |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0016459 | Cellular component | myosin complex |
| GO_0003785 | Molecular function | actin monomer binding |
| GO_0008307 | Molecular function | structural constituent of muscle |
| GO_0032036 | Molecular function | myosin heavy chain binding |
| GO_0005509 | Molecular function | calcium ion binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | MYL2 |
| Protein name | Myosin light chain-2 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (Myosin light chain 2, slow skeletal/ventricular muscle isoform) Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MLC-2) (MLC-2v) (Cardiac myosin light chain 2) (Myosin light chain 2, slow skeletal/ventricular muscle isoform) (MLC-2s/v) (Ventricular myosin light chain 2) Truncated myosin light chain 2 Myosin light chain 2 |
| Synonyms | hCG_40212 MLC2 |
| Description | FUNCTION: Contractile protein that plays a role in heart development and function . Following phosphorylation, plays a role in cross-bridge cycling kinetics and cardiac muscle contraction by increasing myosin lever arm stiffness and promoting myosin head diffusion; as a consequence of the increase in maximum contraction force and calcium sensitivity of contraction force. These events altogether slow down myosin kinetics and prolong duty cycle resulting in accumulated myosins being cooperatively recruited to actin binding sites to sustain thin filament activation as a means to fine-tune myofilament calcium sensitivity to force (By similarity). During cardiogenesis plays an early role in cardiac contractility by promoting cardiac myofibril assembly (By similarity). . |
| Accessions | ENST00000548438.1 A0A191TDH3 A0A590UJU8 A0A7R6M6S5 ENST00000546404.1 A0A7R6RQK5 ENST00000663220.1 P10916 A0A590UK07 G3V1V8 Q6IB42 A0A7R6M8Q8 ENST00000228841.15 |
